Published July 18, 2025
| Version v1
Publication
Restricted
A multicenter observational retrospective study of second-line treatment with daratumumab – bortezomib - dexamethasone (DaraVd) in Multiple Myeloma patients refractory to lenalidomide
Authors/Creators
Contributors
Researcher:
Files
Restricted
The record is publicly accessible, but files are restricted. Log in to check if you have access.